



## Accredo Health, Inc. Selected by Bertek as a Preferred Specialty Pharmacy Provider for APOKYN

April 26, 2004 12:57 PM Eastern Daylight Time

MEMPHIS, Tenn.--(BUSINESS WIRE)--April 26, 2004--Accredo Health, Incorporated (NASDAQ:ACDO) announced today that its wholly owned subsidiary, Nova Factor, Inc. has been selected by Bertek Pharmaceuticals, Inc., a wholly owned subsidiary of Mylan Laboratories, Inc. (NYSE: MYL), as a preferred specialty pharmacy provider of APOKYN(TM) (apomorphine hydrochloride injection). APOKYN is used in the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson's disease.

APOKYN is the first therapy approved in the United States for use as an acute (rescue) treatment of "off" episodes. "Off" episodes are debilitating periods of partial loss of movement or total immobility experienced by patients with Parkinson's disease.

"We are pleased to begin a relationship with such an outstanding drug manufacturer, while assisting patients with Parkinson's disease," said David D. Stevens, Accredo's chairman and chief executive officer. "The addition of this product is another example of the relationships forged by Accredo with the leading manufacturers in the biopharmaceutical industry."

"We are very excited to bring APOKYN to market, and look forward to providing this product to the Parkinson's community. Our relationship with Nova Factor, one of three specialty pharmacy providers we have contracted with, ensures both patients and physicians will have their APOKYN prescription needs fulfilled by a highly respected patient focused organization," stated James Mauzey, President, Bertek Pharmaceuticals, Inc.

As stated by Bertek, the most common side effects of APOKYN in controlled clinical studies were yawning, dyskinesias, nausea and/or vomiting, sleepiness, dizziness, runny nose, hallucinations, fluid retention, chest pain, increased sweating, flushing, and pale complexion.

Accredo's subsidiary, Nova Factor, Inc. has provided specialty pharmaceuticals and quality services for patients with unique medical needs since 1990. The comprehensive services offered by Nova Factor make it easy for physicians and other healthcare providers to help patients with APOKYN therapy.

Through Nova Factor's Assignment of Benefits program, an APOKYN-dedicated team of insurance specialists researches patients' insurance, obtains prior authorization when necessary, files claims on patients' behalf, and bills insurers directly. The APOKYN team is available to answer questions about product availability and patient services at 1-866-898-0104. Nova Factor also has an easy fax referral system that can be accessed when the drug is available (fax 1-866-898-0069).

As part of its service model, Nova Factor's pharmacy team dispenses the drug to the administration location of the healthcare provider's choice. During a patient's course of therapy, Nova Factor's APOKYN-dedicated team will be a resource for patients, caregivers, and healthcare professionals to provide information support.

Accredo Health, Incorporated provides specialized pharmacy and related services pursuant to agreements with biotechnology drug manufacturers relating to the treatment of patients with certain costly, chronic diseases. The Company's services include collection of timely drug utilization and patient compliance information, patient education and monitoring through the use of written materials and telephonic consultation, reimbursement expertise and overnight drug delivery.

In addition to historical information, certain of the statements in the preceding paragraphs, particularly those anticipating future financial performance, business prospects and growth and operating strategies constitute forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words such as anticipate, believe, estimate, expect, intend, predict, hope or similar expressions. Such statements, which include estimated financial information or results and the quoted comments of Mr. Stevens above, are based on management's current expectations and are subject to a number of factors and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements, including, without limitation, the loss of a biopharmaceutical relationship, our inability to sell existing products, difficulties integrating acquisitions, the impact of pharmaceutical industry regulation, the difficulty of predicting FDA and other regulatory authority approvals, the regulatory environment and changes in healthcare policies and structure, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive products and pricing, the ability to obtain products from suppliers, reliance on strategic alliances, the ability to expand through joint ventures and acquisitions, the ability to maintain pricing arrangements with suppliers that preserve margins, the need for and ability to obtain additional capital, the seasonality and variability of operating results, the Company's ability to implement its strategies and achieve its objectives and the risks and uncertainties described in reports filed by Accredo with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation, cautionary statements under the heading "Risk Factors" made in Accredo's Annual Report on Form 10-K for its year ended June 30, 2003.

## Contacts

Accredo Health Inc., Memphis

Financial Contact:

Joel Kimbrough, 901-385-3621

or

Investor Relations Contact:

Kerry Finney, 901-381-7442

[www.accredohealth.com](http://www.accredohealth.com)

